This clinical trial is focused on studying the treatment of relapsing multiple sclerosis (RMS), a condition where the immune system mistakenly attacks the protective covering of nerves, causing communication problems between the brain and the rest of the body. The study will compare the effectiveness and tolerability of a medication called ofatumumab, which is given as a monthly injection under the skin, against other first-line treatments chosen by doctors. These treatments include dimethyl fumarate, diroximel fumarate, interferon beta-1a, glatiramer acetate, teriflunomide, and peginterferon beta-1a. Some of these medications are taken orally, while others are injected.

The purpose of the study is to evaluate how well ofatumumab works compared to these other treatments in people who have recently been diagnosed with RMS and have not yet received treatment. Participants will be randomly assigned to receive either ofatumumab or one of the other treatments. The study will last for about 15 months, during which participants will have regular check-ups to monitor their health and the effectiveness of the treatment. The study will also include a group receiving a placebo, which is a substance with no active medication, to help compare the results.

Throughout the study, researchers will look at various factors, such as the number of relapses, changes in disability levels, and any new brain lesions detected by MRI scans. The goal is to determine which treatment is more effective in preventing relapses and slowing the progression of the disease. Participants will be closely monitored for any side effects or adverse reactions to ensure their safety. This study aims to provide valuable information that could help improve treatment options for people with RMS.